Sotera Health Company (SHC) Financial Ratios

Sotera Health Company (SHC) has an ST Score of 50.1 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on SHC is Buy based on 12 analyst ratings. Our own ST Score grades it C+ (50.1/100). This is data, not investment advice — always do your own research.

Sotera Health Company (SHC) earns a valuation grade of D-, measured against Medical - Diagnostics & Research peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Sotera Health Company (SHC) earns a growth grade of B, measured against Medical - Diagnostics & Research peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Sotera Health Company (SHC) earns a profitability grade of A, measured against Medical - Diagnostics & Research peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Sotera Health Company (SHC) earns a financial strength grade of C-, measured against Medical - Diagnostics & Research peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Sotera Health Company (SHC) is $20.50 from 12 analysts, which is +0.1% versus the recent price of $18.73.

Sotera Health Company (SHC) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.